Novozymes Biopharma will collaborate with Almac to provide a combined service for drug development applications.
Novozymes Biopharma
, part of Novozymes A/S, announced a collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements. The collaboration will allow clients to use Almac’s manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin Flex technology to their peptide and small molecule drugs. Collaborations with commercial partners have already begun and will continue to expand in early 2014.
Novozymes has modified the amino acid sequence of human albumin to increase its receptor affinity, providing properties including improved half-life extension and drug targeting. This technology supplements Almac’s knowledge in peptide and small molecule manufacturing, and can also be associated to its protein conjugation technology offerings. As a result, clients will be able to use Almac’s technology to link Recombumin Flex to their drug products as part of a contract service offering.
Source:
Novozymes Biopharma
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.